Browsing by Author "Kucukoztas, Nadire"

Now showing 1 - 6 of 6

Correlation of Histopahologic Response and Prognostic Markers with Survival in Locally Advanced Non-Small Cell Lung Cancer Patients Who Have Treated with Neoadjuvant Chemotherapy
(2015) Kucukoztas, Nadire; Oguz, Arzu; Rahatli, Samed; Dizdar, Omer; Keskin, Gul Sema Yildiran; Ozyilkan, Ozgur; Altundag, Ozden; 0000-0001-8825-4918; 0000-0003-0197-6622; 0000-0001-5588-0306; 0000-0001-6512-6534; 0000-0003-3163-7429; AAD-2817-2021; W-9219-2019; AAM-3226-2021; W-8004-2019; AAJ-3047-2021
Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone
(2014) Rahatli, Samed; Dizdar, Omer; Kucukoztas, Nadire; Oguz, Arzu; Yalcin, Selim; Ozen, Ozlem; Reyhan, Nihan Haberal; Tarhan, Cagla; Yildiz, Ferah; Dursun, Polat; Altundag, Ozden; Ayhan, Ali
Background: Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB (formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess the outcomes of our patients with stage IB endometrioid endometrial cancer. Materials and Methods: Sixty two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant chemotherapy was not given to any of the patients. Results: Median age was 62 (range, 42-95). Ninety percent of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 93.1%. Conclusions: Patients with stage IB disease in our study demonstrated relatively low recurrence rates with this stage of endometrial cancer.
Is There Any Correlation Between Molecular Subtypes and Blood Groups in Breast Cancer?
(2014) Kucukoztas, Nadire; Oguz, Arzu; Babacan, Taner; Dizdar, Omer; Rahatli, Samed; Sarici, Saim Furkan; Keskin, Gul Sema Yildiran; Diker, Omer; Akin, Serkan; Altundag, Ozden; Altundag, Kadri; https://orcid.org/0000-0001-5588-0306; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0003-3163-7429; https://orcid.org/0000-0001-7162-4812; https://orcid.org/0000-0002-7542-9229; https://orcid.org/0000-0003-0197-6622; AAM-3226-2021; W-8004-2019; AAJ-3047-2021; GWZ-4666-2022; B-8984-2017; W-9219-2019
Paraaortic Lymph Node Dissection in Endometrial Cancer; Is It Necessary?
(2014) Dizdar, Omer; Oguz, Arzu; Kucukoztas, Nadire; Dursun, Polat; Altundag, Ozden; Ayhan, Ali
Response Rates of Taxane Rechallenge in Metastatic Breast Cancer Patients Previously Treated with Adjuvant Taxanes
(2016) Kucukoztas, Nadire; Oguz, Arzu; Rahatli, Samed; Altundag, Ozden; Altundag, Kadri; 0000-0003-0197-6622; 0000-0001-5588-0306; 0000-0003-3163-7429; 0000-0001-6512-6534; 27837607; W-9219-2019; AAM-3226-2021; AAJ-3047-2021; W-8004-2019
Purpose: This study was conducted to determine the efficacy of taxane-based regimens in patients with metastatic breast cancer pre-treated with taxanes in adjuvant treatment and also to assess the response rates of taxanes in each treatment line. Methods: The data of 939 breast cancer patients, who had received adjuvant taxane-based chemotherapy, were reviewed retrospectively. In 191 of them local/distant recurrences were detected. The treatments that were given when metastases occurred and the responses were recorded. Response rates (RRs), clinical benefit rates/CBR (complete response/CR + partial response/PR + stable disease/SD) and progression-free (PFS) and overall survival (OS) values were determined. RRs to the most frequently used protocols in our institutes (capecitabine-based and taxane-based regimens) were compared. Results: Of 191 patients, 11 didn't receive treatment and for the remaining 180 patients 45 (24%) received taxane-based therapies, 89 (49.4%) received capecitabine-based therapies, 28 (15.6%) received hormonotherapy and 18 (10%) received other chemotherapeutics. The RR for first-line taxane regimen was 58.5%, consisting of 5 CRs (12%) and 19 PRs (46%). Menopausal status, histological grade, estrogen/progesterone receptors, cerbB2 status, having PFS > ors 2 years and the site of metastases did not predict response to first-line taxane treatment. For the 2nd and 3rd or later line therapies, RRs of taxane rechallenge were above 40%. Conclusion: Rechallenging with taxanes after (neo)adjuvant taxane exposure seems to be a reasonable option even in 3rd or further line treatments with high response rates.
Response Rates of Taxane Rechallenge in Metastatic Breast Cancer Patients, Previously Treated with Adjuvant Taxanes
(2014) Oguz, Arzu; Babacan, Taner; Dizdar, Omer; Kucukoztas, Nadire; Rahatli, Samed; Keskin, Gul Sema Yildiran; Altundag, Ozden; Altundag, Kadri; https://orcid.org/0000-0001-6512-6534; https://orcid.org/0000-0001-5588-0306; https://orcid.org/0000-0003-3163-7429; https://orcid.org/0000-0003-0197-6622; W-8004-2019; AAM-3226-2021; AAJ-3047-2021; W-9219-2019